Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer 2022-06-06 21:08
Dr Neal Shore joins Clarity's Clinical Advisory Board 2022-05-26 21:08
Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment 2022-03-28 21:06
New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer 2022-03-24 21:08
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial 2022-02-25 22:04
US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer 2022-02-07 22:08
Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial 2022-02-01 21:58
Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics 2021-12-02 21:58
Fifty percent recruitment milestone for PROPELLER prostate cancer trial 2021-12-01 21:57
Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed 2021-11-10 22:06
Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials 2021-09-30 20:03
First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial 2021-08-25 21:18
1 2